| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |